Counting tumor cells in blood predicts treatment benefit in prostate cancer

Jul 06, 2008

Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show.

At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, researchers showed that changes in the number of circulating tumor cells predicted the outcome after chemotherapy in this hard to treat cancer.

"The results add to a growing body of evidence showing that counting these cells is a valuable method for predicting survival and for monitoring treatment benefit in these patients", said Dr. David Olmos from The Royal Marsden NHS Foundation Trust in the UK.

"Our study shows that circulating tumor cell counts could provide information about how patients are responding to therapy earlier than other markers such as prostate-specific antigen (PSA) or time-to-disease progression," he said. "We have observed that patients with declining numbers of circulating tumor cells can see a change in their initial prognosis, reflecting a potential benefit from therapy."

Among the 119 patients in the study, researchers found that those with the lowest circulating cell counts had on average the longest survival.

"Cancer cells can be detected in the circulating blood by a range of methods", Dr. Olmos said. "The technique we used in our study is classified as a cytometric approach. We use an antibody that is widely expressed by epithelial cancer cells, and then use a range of cell-staining techniques to ensure it is a cancer cell."

"Because these circulating cells have broken away from either primary tumors or metastatic sites in other parts of the body, they could potentially be used to help study the specific characteristics of the cancer and perhaps personalize therapy", Dr. Olmos said.

Source: European Society for Medical Oncology

Explore further: Team finds sleep difficulties common among toddlers with psychiatric disorders

add to favorites email to friend print save as pdf

Related Stories

Nanoparticles get a magnetic handle

Oct 09, 2014

A long-sought goal of creating particles that can emit a colorful fluorescent glow in a biological environment, and that could be precisely manipulated into position within living cells, has been achieved ...

'Stealth' nanoparticles could improve cancer vaccines

Oct 01, 2014

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new ...

Tilted acoustic tweezers separate cells gently

Aug 25, 2014

Precise, gentle and efficient cell separation from a device the size of a cell phone may be possible thanks to tilt-angle standing surface acoustic waves, according to a team of engineers.

Recommended for you

Lebanon reports first suspected case of Ebola

51 minutes ago

A Lebanese man who arrived from West Africa is suspected of having Ebola and was quarantined on Thursday in a Beirut hospital, the first such suspected case in the country, Lebanon's health minister said.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

CactusCritter
not rated yet Jul 06, 2008
The term "castration-resistant" tumors is used is this articles. Does it really mean that removal of the prostrate cannot cure the cancer?

Castration refers to testicle removal, so I find uae of the term somewhat unusual.
gdpawel
not rated yet Jul 07, 2008
It would be important to develop a method of in vivo labelling of tumor cells in the circulation and to monitor their trafficking and homing to other sites, such as the leptomeninges. If these cells are viable and therefore able to disseminate, I think the most robust test to this end is to document their ability to metastasize.

Tumor cell release in the circulation after cytotoxic chemotherapy is not new information, since it has been described about 15 years ago by E. Sphall in a paper published in Blood, where they measured tumor cell release in the circulation after stem cell mobilizing chemotherapy and G-CSF support.

What they found was strikingly important, as tumor cells mobilized from the bone marrow (if there was even minimal bone marrow infiltration) and the tumor (if their was residual disease in primary or metastases at the time of peripheral stem cell mobilization) had a temporarily different appearance in the peripheral blood, essentially yielding two distinct peaks; an early one mobilizing with the CD34 PBPCs and the other released later, and thought to represent tumor-derived cells.

The outcome for metabolic responders and non-responders with circulating tumor cell (CTC) monitoring is basically what is going on with a functional profiling assay, showing what patients are benefiting from what drug agents before introducing them into the patient. Monitoring CTCs could be utilized for confirmation after the patient is administered assay-directed most beneficial therapeutic agents.